国内精品伊人久久久久7777_日韩无码三级片免费观看_国产经典aⅴ三级观看_在线播放AV一区

Guangzhou Daily News (all-media reporter Tu Duanyu) In the eyes of the industry, pharmaceutical companies, medical insurance, doctors, patients and other parties have repeatedly tasted the sweetness, the pharmaceutical industry "national negotiations" is expected to be normalized. A few days ago, a new hepatitis B drug that was listed last year and the National Medical Insurance Bureau negotiated successfully. It will enter the national medical insurance reimbursement list next year and be included in the scope of medical insurance fund payment.

It is understood that the National Medical Insurance Bureau is currently launching medical insurance access price negotiations for 128 drugs, and this new drug approved by the national new drug registration on April 12, 2018, is mainly used for chronic hepatitis B treatment. "China has a large number of hepatitis B patients, and hepatitis B is a chronic disease that requires long-term treatment. The relevant new drugs can be quickly negotiated into medical insurance or can greatly improve the 'accessibility' of hepatitis B patients' medication, and can also reduce the economic burden of patients." Industry observers said.

It is understood that China has conducted three rounds of medical insurance drug negotiations in the past three years. In the industry's view, future state negotiations may become the norm. In April 2017, the Ministry of Human Resources and Social Security announced 44 lists of drugs to be negotiated, and 36 drug negotiations were successful with a success rate of 81.8%. Compared with the average retail price in 2016, the average drug price dropped by 44%, up to 70%; in June 2018, the National Medical Insurance Bureau, together with the Ministry of Human Resources and Social Security, the National Health and Health Commission, the Ministry of Finance, etc. Admission to special negotiations. After the National Medical Insurance Bureau negotiated with the enterprise, the final 17 kinds of drugs were successfully negotiated. Compared with the average retail price, the negotiated drug payment standard dropped by an average of 56.7%.